Author's personal copy Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer q (original) (raw)

Abstract

s u m m a r y Objectives: To describe the natural course of distant metastases (DMs) following radiotherapy (RT) or chemoradiotherapy (CRT) in HPV(+) oropharyngeal carcinoma (OPC). Methods: OPC treated with RT/CRT from 1/1/2000 to 5/31/2010 were reviewed. The natural course of DM were compared between HPV(+) and HPV(À) cohorts. Results: Median follow-up was 3.9 years. The DM rate were similar (11% vs. 15% at 3-years, p = 0.25) between the HPV(+) (n = 457) vs. the HPV(À) (n = 167) cases. While almost all (24/25) HPV(À) DM occurred within 2-years following RT (1 was at 2.1 years), 7/54 (13%) of HPV(+) DM were detected beyond 3 years (up to 5.3 years). Disseminating to >2 organs occurred in 18 (33%) HPV(+) vs. none in HPV(À). Post-DM survival rates were 11% vs. 4% at 2-years (p = 0.02) for the HPV(+) vs. HPV(À) cases respectively. 5/6 HPV(+) with lung oligo-metastasis were still alive with stable disease beyond 2-years after salvage procedures for DM (chemotherapy: 3; surgical resec...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (34)

  1. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002;12(6):431-41.
  2. Wolf H, Zur Hausen H, Becker V. EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat New Biol 1973;244(138):245-7.
  3. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92(9):709-20.
  4. Chernock RD, El-Mofty SK, Thorstad WL, Parvin CA, Lewis Jr JS. HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol 2009;3(3):186-94.
  5. Krueger GR, Kottaridis SD, Wolf H, Ablashi DV, Sesterhenn K, Bertram G. Histological types of nasopharyngeal carcinoma as compared to EBV serology. Anticancer Res 1981;1(4):187-94.
  6. Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis 2006;1:23.
  7. Lassen P. The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010;95(3):371-80.
  8. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001;92(4):805-13.
  9. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11(8):781-9.
  10. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24-35.
  11. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 2009;27(12):1992-8.
  12. Xiao WW, Huang SM, Han F, et al. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer 2011;117(9):1874-83.
  13. Daly ME, Le QT, Maxim PG, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2010;76(5):1339-46.
  14. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010;28(27):4142-8.
  15. Huang SH, Perez-Ordonez B, Liu FF, et al. Atypical clinical behavior of p16- confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2011;82:276-83.
  16. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009;27(36):6213-21.
  17. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31(5):1341-6.
  18. Wong K, Huang SH, O'Sullivan B, et al. Point-of-care outcome assessment in the cancer clinic: audit of data quality. Radiother Oncol 2010;95(3):339-43.
  19. RTOG. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clin Adv Hematol Oncol 2007;5(2):79-81.
  20. NCIC Clinical Trials Group. Radiation therapy and cisplatin or panitumumab in treating patients with locally advanced Stage III or Stage IV Head and Neck Cancer (HN6). January 9, 2009.
  21. U.S. National Institutes of Health. Positronic Emmission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumors (PET PREVENT Trial); 2005. <ClinicalTrials.gov>.
  22. Pintilie M. Analysing and interpreting competing risk data. Stat Med 2007;26(6):1360-7.
  23. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011;22(5):1071-7.
  24. Ljumanovic R, Langendijk JA, Hoekstra OS, Leemans CR, Castelijns JA. Distant metastases in head and neck carcinoma: identification of prognostic groups with MR imaging. Eur J Radiol 2006;60(1):58-66.
  25. Coca-Pelaz A, Rodrigo JP, Suarez C. Clinicopathologic analysis and predictive factors for distant metastases in patients with head and neck squamous cell carcinomas. Head Neck 2011.
  26. Spector ME, Gallagher KK, Light E, et al. Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. Head Neck 2012.
  27. Nichols AC, Finkelstein DM, Faquin WC, et al. Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin Cancer Res 2010;16(7):2138-46.
  28. Geara FB, Sanguineti G, Tucker SL, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol 1997;43(1):53-61.
  29. Yen TC, Chang JT, Ng SH, et al. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med 2005;46(3):405-10.
  30. Krabbe CA, Pruim J, Dijkstra PU, et al. 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med 2009;50(12):1940-7.
  31. Chang KP, Hsu CL, Chang YL, et al. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol 2008;44(8):784-92.
  32. Bortolin MT, Pratesi C, Dolcetti R, et al. Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Lett 2006;233(2):247-54.
  33. Singh RK, Maulik S, Mitra S, et al. Human papillomavirus prevalence in postradiotherapy uterine cervical carcinoma patients: correlation with recurrence of the disease. Int J Gynecol Cancer 2006;16(3):1048-54.
  34. Donner A. Approaches to sample size estimation in the design of clinical trials - a review. Stat Med 1984;3(3):199-214.